Poor prognosis childhood cancers;Les cancers de l'enfant de mauvais pronostic

Revue du Praticien

Volumn 57, Issue 10, 2007, Pages 1087-1091

  Valteau Couanet, Dominique ^b   Minard, Véronique ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BUSULFAN; MELPHALAN; THIOTEPA;

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; CHILDHOOD CANCER; DRUG MEGADOSE; EWING SARCOMA; HUMAN; METASTASIS; NEUROBLASTOMA; PROGNOSIS; REMISSION; REVIEW; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; NEOPLASM STAGING; NEOPLASMS; NEUROBLASTOMA; PROGNOSIS; REMISSION INDUCTION; SARCOMA, EWING'S; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 34347396599     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999;23:789-95.
2. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005;6:649-58.
3. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
4. Laprie A, Michon J, Hartmann O, et al. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification. Cancer 2004;101:1081-9.
5. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-14.
6. Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société française des cancers de l'enfant. J Clin Oncol 2006;24:3997-4002.
7. Lafay-Cousin L, Hartmann, Plouvier P, et al. High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study. Bone Marrow Transplant 2000;26:627-32.
8. Lucidarme N, Valteau-Couanet D, Oberlin O, et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant 1998;22:535-40.
9. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997;126:600-7.
10. Avril M, Hartmann O, Valteau-Couanet D, et al. Antiinfective prophylaxis with ceftazidime and teicoplanin in children undergoing high-dose chemotherapy and bone marrow transplantation. Pediatr Hematol Oncol 1994;11:63-73.
11. Brugières L, Hartmann O, Benhamou E, et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant 1988;3:53-8.